Vidalista 20 (Tadalafil Tablets I.P. 20 mg)

Vidalista 20 (Tadalafil Tablets I.P. 20 mg) — Comprehensive Medical Information

Overview

Vidalista 20 contains Tadalafil 20 mg, a selective phosphodiesterase-type 5 (PDE5) inhibitor used primarily for the management of erectile dysfunction (ED) in adult men.
It is produced by Centurion Remedies Pvt. Ltd., a GMP-certified Indian pharmaceutical manufacturer.

Tadalafil enhances blood flow to specific vascular tissues through vasodilation mediated by cyclic GMP.
Because of its long elimination half-life (approximately 17 hours), the clinical effect of Vidalista 20 may persist for up to 36 hours, distinguishing it from shorter-acting PDE5 inhibitors such as sildenafil.

Pharmacological Class and Composition

Parameter	Details
Generic name	Tadalafil
Brand name	Vidalista 20
Dosage strength	20 mg per tablet
Pharmacological class	Phosphodiesterase-5 inhibitor
Manufacturer	Centurion Remedies Pvt. Ltd.
Route of administration	Oral
Legal status	Prescription-only medicine (Rx)
Pharmacopoeial standard	Indian Pharmacopoeia (I.P.)

Mechanism of Action

Erection of the penis results from relaxation of smooth muscle in the corpus cavernosum and the subsequent increase in penile blood flow.
Sexual stimulation triggers the release of nitric oxide (NO) from nerve endings and endothelial cells, activating guanylate cyclase and increasing intracellular cyclic guanosine monophosphate (cGMP).

cGMP induces smooth-muscle relaxation, allowing vascular expansion and engorgement of erectile tissue.
The enzyme PDE5 degrades cGMP, terminating the erection.

Tadalafil selectively inhibits PDE5, thereby sustaining cGMP levels, enhancing vasodilation, and promoting normal erectile function in response to sexual stimulation.

Important: Tadalafil has no effect without sexual arousal; it does not cause spontaneous erection.

Therapeutic Indications

Tadalafil is approved for several clinical indications:

1. Erectile Dysfunction (ED)
   • Restoration of erectile function in adult males when inadequate erection prevents satisfactory sexual activity.
2. Benign Prostatic Hyperplasia (BPH) (in lower doses)
   • Relief of lower urinary-tract symptoms such as hesitancy, weak stream, and nocturia via smooth-muscle relaxation in the prostate and bladder neck.
3. Pulmonary Arterial Hypertension (PAH) (specialist use)
   • Reduction of pulmonary vascular resistance and improvement in exercise capacity.

Note: Vidalista 20 is formulated for ED therapy; BPH or PAH uses employ lower or differently labeled strengths under specialist supervision.

Pharmacokinetics

Parameter	Characteristics
Absorption	Rapid; peak plasma levels within 2 hours of dosing
Bioavailability	≈ 80 %
Protein binding	~ 94 %
Metabolism	Predominantly hepatic, via CYP3A4
Elimination half-life	~ 17.5 hours
Onset of action	30 – 45 minutes
Duration of action	Up to 36 hours
Excretion	~ 60 % fecal, 36 % urinary (metabolites)

The long half-life underlies Tadalafil’s prolonged pharmacologic window, often referred to as the “weekend effect.”

Dosage and Administration

General guidance

• Always use Tadalafil exactly as prescribed by a qualified healthcare professional.
• Swallow tablets whole with water; may be taken with or without food.
• Avoid excessive alcohol intake, which may potentiate hypotension.

Recommended dosing

Indication	Typical Dose	Frequency
Erectile Dysfunction	10 mg to 20 mg before anticipated sexual activity	Not more than once per 24 hours
Daily therapy (chronic ED/BPH)	2.5 – 5 mg once daily	Taken at the same time each day

Vidalista 20 represents a moderate dose appropriate for patients who require stronger efficacy than 10 mg but less than high-strength (40 mg) regimens.

Target Population

• Adult men aged 18 years or older with clinically diagnosed ED.
• Patients who failed to respond adequately to first-line non-pharmacologic or psychotherapeutic measures.
• Men seeking on-demand pharmacologic assistance for sexual performance under physician guidance.
• Not intended for women, adolescents, or individuals without erectile impairment.

Key Clinical Benefits

1. Improved erectile rigidity and maintenance through enhanced penile perfusion.
2. Rapid onset and extended duration enabling flexible timing.
3. High efficacy rate documented across multiple randomized clinical trials.
4. Improved sexual confidence and relationship satisfaction.
5. Well-tolerated safety profile when used under medical supervision.
6. Minimal interference from food intake.
7. Predictable pharmacokinetics ensuring consistent results.

Problem Addressed: Erectile Dysfunction

Erectile dysfunction is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
It can arise from vascular insufficiency, neurological impairment, hormonal imbalance, psychological stress, or adverse drug effects.

Prevalence increases with age and chronic diseases such as diabetes mellitus, hypertension, and coronary artery disease.
ED often causes profound emotional and relational stress, diminishing self-esteem and overall quality of life.

By inhibiting PDE5, Vidalista 20 restores physiological erectile function, offering an evidence-based solution to one of the most prevalent male sexual-health disorders.

Contraindications

Tadalafil must not be used in the following situations:

• Concurrent use of organic nitrates or nitric-oxide donors (e.g., glyceryl trinitrate, isosorbide dinitrate, “poppers”).
• Known hypersensitivity to tadalafil or excipients.
• Severe cardiac disease (recent myocardial infarction < 90 days, unstable angina, severe heart failure).
• Recent stroke (within 6 months).
• Severe hepatic impairment (Child-Pugh C) or severe renal failure.
• Uncontrolled hypotension (< 90/50 mmHg) or uncontrolled hypertension (> 170/100 mmHg).
• Hereditary degenerative retinal disorders such as retinitis pigmentosa.

Warnings and Precautions

1. Cardiovascular assessment:
   Sexual activity poses a cardiac workload; patients with cardiovascular risk factors must be evaluated before prescription.
2. Priapism:
   Painful erection lasting > 4 hours requires emergency care to prevent permanent tissue damage.
3. Ocular or auditory effects:
   Rare instances of non-arteritic anterior ischemic optic neuropathy (NAION) and sudden hearing loss have been reported. Discontinue immediately if such symptoms occur.
4. Renal/hepatic impairment:
   Dosage adjustment or avoidance of high doses is advised.
5. Drug interactions:
   • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) elevate plasma tadalafil concentrations.
   • CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) may reduce efficacy.
   • Concomitant use with antihypertensives can enhance hypotensive effects.
6. Alcohol and grapefruit juice may exacerbate side effects or alter metabolism.

Adverse Reactions

Common (≥1 %)	Uncommon (<1 %)	Rare (<0.1 %) / Serious
Headache	Dizziness	Priapism
Flushing	Nasal congestion	Vision or hearing loss
Dyspepsia	Myalgia	Hypersensitivity reactions
Back pain	Sinusitis	Hypotension/syncope

Most effects are dose-dependent and transient, resolving without intervention.

Overdose Management

Symptoms: Severe headache, prolonged erection, dizziness, hypotension.
Treatment: Supportive care, cardiovascular monitoring, oxygenation, and fluid replacement.
Note: Hemodialysis is ineffective due to high plasma protein binding.

Special Populations

Group	Recommendation
Elderly (> 65 years)	Use lowest effective dose; monitor blood pressure.
Renal impairment	Avoid 20 mg in moderate-to-severe cases.
Hepatic impairment	Contraindicated in severe dysfunction.
Pediatric use	Not indicated.
Women	Not indicated.

Storage and Handling

• Store below 30 °C, protected from light and moisture.
• Keep in original blister packaging until use.
• Do not use past expiry date printed on carton.
• Keep out of reach of children and pets.

Patient Counselling Information

Healthcare professionals should advise patients that:

1. Tadalafil should be taken only on medical prescription.
2. The drug facilitates erection only with sexual stimulation.
3. Avoid combining with nitrates or recreational “poppers.”
4. Moderate alcohol use; avoid large quantities.
5. Report sudden vision, hearing, or prolonged erection immediately.
6. Lifestyle modifications (exercise, weight control, smoking cessation) improve outcomes.

Clinical Outcomes and Efficacy Data

• Multicenter randomized trials demonstrate successful intercourse rates of 65–80 % with tadalafil 20 mg, significantly higher than placebo (~35 %).
• Benefits observed across age groups, diabetes, and cardiovascular comorbidities.
• Onset ≈ 30 minutes, median efficacy duration ≈ 33 hours.
• Patient satisfaction scores remain high due to extended window and tolerability.

Educational Summary

Vidalista 20 (Tadalafil Tablets 20 mg) is a moderate-strength PDE5 inhibitor that effectively treats erectile dysfunction by enhancing blood flow to penile tissues.
Its prolonged half-life provides flexibility, allowing men to plan sexual activity without strict timing constraints.

When used responsibly under medical supervision, it offers significant improvement in sexual function, psychological wellbeing, and relationship satisfaction.
However, unsupervised or recreational use carries medical risk; proper diagnosis and follow-up are essential.

Legal and Regulatory Disclaimer

This document is intended solely for healthcare education and informational purposes.
Vidalista 20 (Tadalafil Tablets I.P. 20 mg) is a prescription-only medicine.
Patients must consult a licensed physician before starting or modifying therapy.
The content does not constitute medical advice, diagnosis, or endorsement of any product.
Always follow professional guidance and local regulatory frameworks governing prescription medications.

References

1. U.S. FDA — Cialis (Tadalafil) Prescribing Information.
2. European Medicines Agency — Tadalafil Assessment Report.
3. Indian Pharmacopoeia 2022 — Tadalafil Monograph.
4. World Health Organization — Guidelines on Sexual and Reproductive Health.
5. Centurion Remedies Pvt. Ltd — Product Specification Sheet.

Conclusion

Vidalista 20 (Tadalafil Tablets 20 mg) remains a well-established therapeutic option for erectile dysfunction when prescribed responsibly.
By improving penile blood flow through selective PDE5 inhibition, it restores natural erectile response and enhances sexual confidence.
Its favorable pharmacokinetic profile, durable effect, and clinical validation make it a reliable agent for physicians managing ED — provided that comprehensive counselling and monitoring accompany its use.